Merck reshuffled its senior management, consolidating sales and marketing leadership for U.S. human health under president Bradley Sheares and moving Margaret McGlynn, formerly co-president of U.S. human health, to head up its vaccines division.
McGlynn had led hospital and specialty sales, marketing, marketing services and managed care, all areas that will now be handled by Sheares. She replaces Adel Mahmoud as president of Merck Vaccines and takes on responsibility for Merck’s joint venture with Sanofi Aventis. Mahmoud faces mandatory retirement on Sep. 6, when he turns 65. He will serve on Merck’s management committee as chief medical advisor for vaccines and infectious diseases.
Sheares will assume responsibility for the entire U.S. human health division.
Judy Lewent, executive vice president and chief financial officer, will assume responsibility for strategic planning, in addition to her previous duties which include business development, licensing, Merck Capital Ventures and the joint ventures with Merial and Johnson & Johnson, AstraZeneca and DuPont.
Lewent hands responsibility for human health Asia Pacific off to David Anstice, who previously headed Japan, Australia and New Zealand, as well as the firm’s joint venture with Schering-Plough. Per Wold-Olsen, president of human health for Europe, the Middle East and Africa, will also take on Canada and Latin America. He continues to manage worldwide human health marketing and Merck’s new business efforts in India.
Sheares to head Merck marketing as McGlynn leads vaccines
Merck reshuffled its senior management, consolidating sales and marketing leadership for U.S. human health under president Bradley Sheares and moving Margaret McGlynn, formerly co-president of U.S. human health, to head up its vaccines division.
